At more than $200 per share bid, CVS Health is reportedly in negotiations to buy the health insurance giant Aetna.
At more than $200 per share bid, CVS Health is reportedly in negotiations to buy the health insurance giant Aetna. According to The Wall Street Journal, the total deal is worth more than $66 billion.
The merger could mean the 46.7 million Aetna members could access convenient MinuteClinics run by CVS Health in its stores, in addition to the company’s retail pharmacies. It’d also give members the opportunity for improved care coordination.
If the merger is realized, CVS would wield a significant dominance within the healthcare world, being the largest retail pharmacy chain in the United States, a pharmacy benefit manager (PBM), and potentially one of the largest health insurance businesses. However, the 2 companies could face legal roadblocks, considering recent challenges faced by such announcements—a federal judge ruling blocked the Aetna—Humana ($34 billion) and Anthem–Cigna ($54 billion) mergers earlier this year.
"A monopoly of our healthcare system is not good for any American. We are very concerned about CVS Health acquiring Aetna and the adverse impact that this will have on cancer patients," said Ted Okon, MBA, executive director of the Community Oncology Alliance, in an e-mail. "CVS controls the largest PBM, a national chain of pharmacies, a mail order pharmacy, and a medical plan sponsor. As it is, cancer patients experience delays in getting critical therapy, switched treatment without their physicians’ knowledge, and higher medication costs. It will be a disaster if CVS is now allowed to control one of the largest national insurers." Okon worries that the merger will further drive up healthcare costs for average Americans.
For CVS, this deal might also be in preparation for Amazon’s foray into the pharmaceutical business, following rumors last month that the retail giant was talking to mid-size pharmacy benefit managers for contracts.
At market close on Thursday, which was when The Journal posted the news, Aetna shares climbed almost 12% while CVS saw a drop of about 3%.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Value-Based Care Is Key to Bringing Cardiology Breakthroughs to Those Who Will Benefit Most
March 13th 2025On December 10, 2024, cardiologists, researchers, and value-based care experts gathered in Dallas, Texas, to discuss best practices for implementing advances in cardiology care with a value-based mindset, spanning the care continuum from prevention to treatment.
Read More
Addressing Financial Aid and Patient Independence as Part of Atopic Dermatitis Care
March 13th 2025Discussions centered on mitigating the financial burden of pediatric atopic dermatitis through financial aid programs and enhancing support for young patients to independently manage their condition were emphasized at this year’s 2025 American Academy of Dermatology meeting.
Read More